Task: Answer Verification
Input (English): Question: Are the pharmacokinetics of liposomal encapsulated daunorubicin modified by HAART in patients with HIV-associated Kaposi 's sarcoma?
Answer: Our data show that there are no significant differences in the pharmacokinetic parameters of daunorubicin in patients receiving DaunoXome in combination with indinavir and ritonavir compared with those in patients not receiving PIs. Therefore in patients affected by AIDS-related KS treated with Highly Active AntiRetroviral Therapy (HAART) there is no pharmacokinetic justification for reducing the doses of DaunoXome.
Output (English): no